---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-070834"
form_type: "8-K"
ticker: "BRNS"
cik: "0001828185"
company_name: "Barinthus Biotherapeutics plc."
filed_at: "2024-06-12T23:59:59+00:00"
generated_at: "2026-06-01T04:54:14.146366+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Barinthus prioritizes VTP-300 (CHB) and VTP-1000 (celiac); cuts workforce 25%, extends cash runway to Q2 2026

## Summary
- Pipeline focused on VTP-300 for chronic hepatitis B and VTP-1000 for celiac disease; ongoing Phase 1 trial of VTP-850 in prostate cancer to be completed.
- Company to undergo restructuring with workforce reduction of approximately 25% to align resources.
- Cash runway expected to extend into second quarter of 2026 due to streamlined pipeline and cost cuts.

## SEC filing metadata
- accession: 0001104659-24-070834
- form_type: 8-K
- ticker: BRNS
- cik: 0001828185
- company_name: Barinthus Biotherapeutics plc.
- filed_at: 2024-06-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828185/000110465924070834/0001104659-24-070834-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828185/000110465924070834/tm2417037d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-070834
- JSON: https://secwatch.observer/filing/0001104659-24-070834.json
- Plain text: https://secwatch.observer/filing/0001104659-24-070834.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.